Articles

Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma

Explosive Development of BCMA CAR T-Cell Therapies for Multiple Myeloma

By Phoebe Starr

TON - April 2019, Vol 12, No 2

San Diego, CA—A dizzying array of new chimeric antigen receptor (CAR) T-cell therapies targeting the B-cell maturation antigen (BCMA) designed specifically for the treatment of multiple myeloma was presented at ASH 2018. BCMA-targeted CAR T-cell therapies are designed to improve T-cell persistence, depth of response, and tolerability. Response rates reported at ASH 2018 range from 70% to 100%, depending on the patient population and the use of previous regimens. Read More ›

Cedars-Sinai Blood & Marrow Transplant Program: Committed to Excellence

Cancer Center Profile

TON - April 2019, Vol 12, No 2

The Cedars-Sinai Blood & Marrow Transplant Program, Los Angeles, CA, has performed more than 2200 stem-cell and bone marrow transplants since its inception in 1990. The program is accredited for autologous and allogeneic transplant by the Foundation for the Accreditation of Cellular Therapy and is a National Marrow Donor Program/Be The Match Transplant Center. It has also been recognized as a Blue Cross Center of Medical Excellence, a designation awarded to select hospitals that meet evidence-based standards and provide high-quality care for patients. Read More ›

In the Literature

In the Literature

TON - April 2019, Vol 12, No 2

Currently, there are limited therapies to prevent or delay recurrence in advanced ovarian cancer, with approximately 70% of patients having a recurrence within 3 years. The effectiveness of olaparib, an oral poly (ADP-ribose) polymerase inhibitor, in relapsed disease has been well-established; however, its benefit as a maintenance therapy in newly diagnosed advanced ovarian cancer is uncertain. Read More ›

April 16, 2019 – FDA Approvals, News & Updates

By Yvette Florio Lane

FDA Updates, In the News, Lung Cancer

FDA Approves Keytruda for First-Line Treatment of Non–Small-Cell Lung Cancer (TPS ≥1%)
FDA Advises Women to Avoid Pregnancy for Only 2 Months After Final Dose of Soltamox

Navigating Hematologic Malignancies

By Peg Rummel, RN, MHA, OCN, NE-BC

Best Practices in Patient Navigation – Navigating Hematologic Malignancies

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

By Yvette Florio Lane

Breast Cancer, FDA Updates, In the News

On April 4, 2019, the US Food and Drug Administration (FDA) expanded the indication of palbociclib (Ibrance; Pfizer), a kinase inhibitor, in combination with specific endocrine therapies for men with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. This is the first hormonal-based therapy to be approved for men. Read More ›

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

By Yvette Florio Lane

Breast Cancer, FDA Updates, In the News

On March 27, 2019, the US Food and Drug Administration (FDA) issued an alert from its Office of Women’s Health announcing that, after more than 20 years of regulatory oversight, the agency is proposing amendments to the existing policy governing mammography services. Read More ›

FDA Approves Tecentriq plus Chemotherapy for First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer

By Yvette Florio Lane

FDA Updates, In the News, Lung Cancer

For the second time this month, the FDA has given an approval to Genentech’s PD-L1 inhibitor, Tecentriq. Read More ›

Next-Generation Sequencing Testing in Oncology

Faculty Perspectives: Next-Generation Sequencing Testing in Oncology | Part 4 of a 4-Part Series

Following the advent of molecularly targeted agents, and more recently, immunotherapy, over the past few decades, we have witnessed dramatic changes in the treatment paradigms for many types of cancer. Read More ›

Clinical Application of Next-Generation Sequencing in Oncology

Faculty Perspectives: Next-Generation Sequencing Testing in Oncology | Part 4 of a 4-Part Series

The clinical application of assays that utilize next-generation sequencing (NGS) technology is accelerating rapidly in the field of oncology. Read More ›

Page 152 of 376

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

TON Print Edition

TON Weekly e‑Newsletter

I have reviewed and consent to the terms of TON's Privacy Policy, and TON has my permission to retain my information in its database, and to forward pertinent communications to me.